Persistent Disease Activity Remains a Burden for Patients with Systemic Lupus Erythematosus
Authors:
- Christine A. PeschkenCPChristine A. Peschken
- Yishu WangYWYishu Wang
- Michal AbrahamowiczMAMichal Abrahamowicz
- Janet PopeJPJanet Pope
- Earl SilvermanESEarl Silverman
- Amyn SayaniASAmyn Sayani
- Sandra IczkovitzSISandra Iczkovitz
- Jorge RossJRJorge Ross
- Michel ZummerMZMichel Zummer
- Lori TuckerLTLori Tucker
- Christian PineauCPChristian Pineau
- Deborah LevyDLDeborah Levy
- 15 September 2018
- journal article
- research article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 46 (2) , 166-175
Abstract
Objective.: Persistent systemic lupus erythematosus (SLE) disease activity is associated with increased morbidity and mortality. In a multicenter cohort of patients with prevalent SLE, we described persistence, patterns, and predictors of change in disease activity over time.Methods.: Based on SLE Disease Activity Index (SLEDAI)-2K scores at cohort entry, patients were classified into 4 groups: low (score < 4; LOW), moderate (4 to < 6; MOD), moderately high (6 to ≤ 10; MHIGH), and very high (> 10; VHIGH). Multivariable linear and longitudinal mixed linear regression models were used to identify predictors of change over time in SLEDAI-2K.Results.: There were 2019 participants, with declining followup data over 5 years (1326, 580, 274, 186, and 148 patients, respectively). At cohort entry, mean (± SD) age was 42 (± 17) years, disease duration 11 (± 10) years, and 90% were female. The 4 groups included 44% LOW (n = 891), 20% MOD (n = 400), 22% MHIGH (n = 442), and 14% VHIGH (n = 286); therefore, 36% had clinically important SLE activity. The proportion of patients in the LOW group at entry who moved to a higher activity level varied from 30% (167/557) at 1 year, to 49% (41/83) at 3 years, and 54% (30/56) at 5 years. Among 181 patients with MOD to VHIGH entry activity and 3 years of followup, 116 (64.1%) remained active. In all analyses, only higher SLEDAI-2K at cohort entry remained a significant predictor of higher SLEDAI-2K in subsequent years.Conclusion.: Higher SLEDAI-2K at study entry was the single major independent predictor of higher SLEDAI-2K over time, reflecting frequent persistence of active disease, even in patients with longstanding disease. This highlights gaps in the optimal treatment of SLE.Keywords
This publication has 42 references indexed in Scilit:
- Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double‐Blind, Phase III StudyArthritis & Rheumatism, 2013
- Unmet medical needs in systemic lupus erythematosusArthritis Research & Therapy, 2012
- Multiple imputation using chained equations: Issues and guidance for practiceStatistics in Medicine, 2010
- Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosusLupus, 2010
- The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patientsRheumatology, 2010
- Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trialArthritis & Rheumatism, 2009
- Prednisone, Lupus Activity, and Permanent Organ DamageThe Journal of Rheumatology, 2009
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992
- Derivation of the sledai. A disease activity index for lupus patientsArthritis & Rheumatism, 1992
- A new look at the statistical model identificationIEEE Transactions on Automatic Control, 1974